Drug Trial Radar · NCT06850805
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Mar 31, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Optinose US Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Paratek Pharmaceuticals Inc
- First posted
- Feb 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.
Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
Interventions
OPN-375Drug
OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
PlaceboDrug
Placebo solution administered via exhalation delivery system (EDS).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to the end of Week 4 in the average instantaneous CSS (evaluation of symptom severity immediately preceding the time of scoring).Time frame: 4 Weeks
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
North Alabama ENT
Huntsville, Alabama · Not yet recruiting
San Tan Allergy & Asthma
Gilbert, Arizona · Withdrawn
Childrens Hospital of Los Angeles
Los Angeles, California · Not yet recruiting
Children's Hospital of Orange County
Orange, California · Recruiting
DaVinci Research, LLC
Sacramento, California · Recruiting
Rady Childrens Hospital San Diego
San Diego, California · Not yet recruiting
Breathe Clear Institute
Torrance, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Colorado ENT & Allergy
Colorado Springs, Colorado · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Not yet recruiting
Southern Illinois University School of Medicine
Springfield, Illinois · Recruiting
Kentuckiana ENT
Louisville, Kentucky · Recruiting
Centers for Advanced ENT Care
Towson, Maryland · Recruiting
University of Missouri Medical Center
Columbia, Missouri · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
Allergy, Asthma and Clinical Research Center
Oklahoma City, Oklahoma · Recruiting
Vital Prospects Clinical Research Institute
Tulsa, Oklahoma · Recruiting
Charleston ENT & Allergy
North Charleston, South Carolina · Recruiting
Carolina ENT Clinic/CENTRI Inc.
Orangeburg, South Carolina · Recruiting
Orion Clinical Research
Austin, Texas · Recruiting
STAAMP Research
San Antonio, Texas · Recruiting
Alamo ENT Associates
San Antonio, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
EVMS at Old Dominion University
Norfolk, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.